Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 282.2
(-4.98%)
SEK 282.2
(-4.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 19.58 Billion SEK | 153.02% |
| 2022 | 7.73 Billion SEK | -21.52% |
| 2021 | 9.86 Billion SEK | -30.39% |
| 2020 | 14.16 Billion SEK | -10.47% |
| 2019 | 15.82 Billion SEK | 628.18% |
| 2018 | -2.99 Billion SEK | -1828.89% |
| 2017 | 173.27 Million SEK | -91.43% |
| 2016 | 2.02 Billion SEK | 1963.6% |
| 2015 | -108.5 Million SEK | -139.8% |
| 2014 | 272.62 Million SEK | -21.13% |
| 2013 | 345.67 Million SEK | 141.65% |
| 2012 | 143.04 Million SEK | 165.31% |
| 2011 | -219.04 Million SEK | -108.15% |
| 2010 | 2.68 Billion SEK | 1390.95% |
| 2009 | -208.28 Million SEK | 18.07% |
| 2008 | -254.22 Million SEK | 30.5% |
| 2007 | -365.79 Million SEK | 2.88% |
| 2006 | -376.64 Million SEK | 64.42% |
| 2005 | -1.05 Billion SEK | -1721.45% |
| 2004 | -58.11 Million SEK | 51.92% |
| 2003 | -120.89 Million SEK | -14.52% |
| 2002 | -105.56 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 16.88 Billion SEK | 5.86% |
| 2024 Q2 | 16.31 Billion SEK | -12.71% |
| 2024 Q1 | 18.69 Billion SEK | -4.54% |
| 2023 Q4 | 19.58 Billion SEK | -3.96% |
| 2023 Q1 | 9.03 Billion SEK | 16.76% |
| 2023 Q3 | 20.38 Billion SEK | -25.57% |
| 2023 FY | 19.58 Billion SEK | 153.02% |
| 2023 Q2 | 27.39 Billion SEK | 203.14% |
| 2022 Q1 | 8.71 Billion SEK | -11.67% |
| 2022 Q3 | 9.89 Billion SEK | 4.23% |
| 2022 Q2 | 9.49 Billion SEK | 8.99% |
| 2022 FY | 7.73 Billion SEK | -21.52% |
| 2022 Q4 | 7.73 Billion SEK | -21.79% |
| 2021 Q1 | 13.07 Billion SEK | -7.7% |
| 2021 Q4 | 9.86 Billion SEK | -14.29% |
| 2021 Q3 | 11.5 Billion SEK | -0.7% |
| 2021 Q2 | 11.58 Billion SEK | -11.39% |
| 2021 FY | 9.86 Billion SEK | -30.39% |
| 2020 FY | 14.16 Billion SEK | -10.47% |
| 2020 Q1 | 14.6 Billion SEK | -7.7% |
| 2020 Q2 | 12.27 Billion SEK | -15.93% |
| 2020 Q3 | 13.15 Billion SEK | 7.1% |
| 2020 Q4 | 14.16 Billion SEK | 7.73% |
| 2019 Q3 | 7.99 Billion SEK | 67.06% |
| 2019 FY | 15.82 Billion SEK | 628.18% |
| 2019 Q1 | 5.94 Billion SEK | 298.55% |
| 2019 Q2 | 4.78 Billion SEK | -19.57% |
| 2019 Q4 | 15.82 Billion SEK | 97.99% |
| 2018 FY | -2.99 Billion SEK | -1828.89% |
| 2018 Q3 | -2.48 Billion SEK | -7.95% |
| 2018 Q2 | -2.3 Billion SEK | -31.86% |
| 2018 Q1 | -1.74 Billion SEK | -1107.06% |
| 2018 Q4 | -2.99 Billion SEK | -20.6% |
| 2017 Q4 | 173.27 Million SEK | 113.83% |
| 2017 Q3 | -1.25 Billion SEK | -82.92% |
| 2017 Q2 | -685 Million SEK | -29.73% |
| 2017 Q1 | -528 Million SEK | -126.11% |
| 2017 FY | 173.27 Million SEK | -91.43% |
| 2016 Q1 | -305 Million SEK | -181.1% |
| 2016 Q2 | -266 Million SEK | 12.79% |
| 2016 Q3 | -320 Million SEK | -20.3% |
| 2016 Q4 | 2.02 Billion SEK | 731.89% |
| 2016 FY | 2.02 Billion SEK | 1963.6% |
| 2015 Q2 | 58 Million SEK | -57.66% |
| 2015 FY | -108.5 Million SEK | -139.8% |
| 2015 Q3 | -92 Million SEK | -258.62% |
| 2015 Q4 | -108.5 Million SEK | -17.94% |
| 2015 Q1 | 137 Million SEK | -49.75% |
| 2014 Q1 | 222.1 Million SEK | -35.75% |
| 2014 Q3 | 205.8 Million SEK | -34.35% |
| 2014 Q4 | 272.62 Million SEK | 32.47% |
| 2014 FY | 272.62 Million SEK | -21.13% |
| 2014 Q2 | 313.5 Million SEK | 41.15% |
| 2013 Q1 | 399.5 Million SEK | 179.27% |
| 2013 FY | 345.67 Million SEK | 141.65% |
| 2013 Q4 | 345.67 Million SEK | -0.24% |
| 2013 Q3 | 346.5 Million SEK | -4.6% |
| 2013 Q2 | 363.2 Million SEK | -9.09% |
| 2012 Q1 | 1.36 Billion SEK | 724.08% |
| 2012 Q2 | 706.7 Million SEK | -48.3% |
| 2012 Q3 | 636.9 Million SEK | -9.88% |
| 2012 Q4 | 143.04 Million SEK | -77.54% |
| 2012 FY | 143.04 Million SEK | 165.31% |
| 2011 FY | -219.04 Million SEK | -108.15% |
| 2011 Q1 | 2.71 Billion SEK | 1.14% |
| 2011 Q2 | 1.99 Billion SEK | -26.77% |
| 2011 Q3 | 1.92 Billion SEK | -3.44% |
| 2011 Q4 | -219.04 Million SEK | -111.39% |
| 2010 FY | 2.68 Billion SEK | 1390.95% |
| 2010 Q4 | 2.68 Billion SEK | -3.96% |
| 2010 Q3 | 2.79 Billion SEK | 127.94% |
| 2010 Q2 | 1.22 Billion SEK | 1.09% |
| 2010 Q1 | 1.21 Billion SEK | 683.35% |
| 2009 Q4 | -208.28 Million SEK | 0.0% |
| 2009 FY | -208.28 Million SEK | 18.07% |
| 2008 FY | -254.22 Million SEK | 30.5% |
| 2007 FY | -365.79 Million SEK | 2.88% |
| 2006 FY | -376.64 Million SEK | 64.42% |
| 2005 FY | -1.05 Billion SEK | -1721.45% |
| 2004 FY | -58.11 Million SEK | 51.92% |
| 2003 FY | -120.89 Million SEK | -14.52% |
| 2002 FY | -105.56 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 101851.195% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 67388.66% |
| BioGaia AB (publ) | -1.53 Billion SEK | 1375.309% |
| Enzymatica AB (publ) | 17.73 Million SEK | -110296.347% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | 342604.81% |
| Gabather AB (publ) | -1.11 Million SEK | 1756243.498% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | -110620.95% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 35180.082% |
| Nanexa AB (publ) | -61.13 Million SEK | 32128.592% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 128055.303% |
| ODI Pharma AB | -2.63 Million SEK | 742393.319% |
| Orexo AB (publ) | 302.8 Million SEK | -6366.645% |
| Probi AB (publ) | -275.85 Million SEK | 7198.346% |
| Swedencare AB (publ) | 1.42 Billion SEK | -1277.682% |
| Toleranzia AB | -17.45 Million SEK | 112286.318% |
| Vivesto AB | -1.29 Million SEK | 1507490.3% |